Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
about
CIViC databaseRole of targeted therapy in metastatic colorectal cancerTherapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidenceMolecular pathology of cancer: how to communicate with diseaseMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerTrastuzumab in the management of gastroesophageal cancer: patient selection and perspectivesTranslating genomic profiling to gastrointestinal cancer treatment.FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical RelevanceDetection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA.HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.Molecular Testing for Gastrointestinal Cancer.Targeted therapies in breast cancer: New challenges to fight against resistance.Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives.Genetic and epigenetic markers in colorectal cancer screening: recent advances.Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies.Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience.From tumour heterogeneity to advances in precision treatment of colorectal cancer.Current and future biomarkers in the treatment of colorectal cancer.Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2.Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies.Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence.Cancer predisposition syndromes: lessons for truly precision medicine.Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the piePlasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.What We Know About Stage II and III Colon Cancer: It's Still Not Enough.Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment.Biologics in bowel cancer.Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis.Copy number variations in DCC/18q and ERBB2/17q are associated with disease-free survival in microsatellite stable colon cancer.Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience.Recent developments in the treatment of metastatic colorectal cancer.Targeted therapies for gastric cancer: failures and hopes from clinical trialsClinical utility of circulating cell-free DNA in advanced colorectal cancer.Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient.Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation.Taking aim at the genomic diversity of gastrointestinal cancers: a changing landscape
P2860
Q27612411-012DD923-EBCB-48EC-A317-9C691C98072EQ28068817-B4C56FE5-E977-4FAF-AAEA-7908A00B8E08Q28071772-43EF78F9-EEAC-4DC4-94E8-D4B52955BD8EQ28076360-32FD00D4-86B8-4237-85CF-3AA2118E4A49Q28076490-B83CDB35-7318-4266-BBA6-BA19D4EF4B97Q28077666-0FC9244F-6185-4780-822F-193AD1441EF1Q30239109-7851DD56-98C9-4DC8-B119-82AF7B20B9D7Q33607015-DD6932FF-F066-403B-9595-3AFF89262FEDQ33898865-671A008D-5F61-42A8-86D2-AB6FD3F07BF9Q37708897-CE7A132B-DB30-469A-9172-EB70700D30A3Q37710556-2D0F35F5-7548-495C-8537-175E6DCB1DAFQ37743048-78F6AC20-6EF3-4598-B0FF-02D2634C2564Q38376337-095C7559-C2AF-4419-AF1F-D39F55EFEF0AQ38648300-9596E080-105B-49CA-8B43-F1503F01044DQ38650454-8ED12CFE-2B74-4E4A-B7B4-5BF2F07ABADBQ38676702-D4F155F8-6211-40DD-BBE4-13B615F173F8Q38679229-F0E6BE9B-ECBF-4E21-BAAE-DBBACBCCB038Q38690672-09FE2AC7-C40C-4A3E-B919-FF46EC417C35Q38698206-7BC70973-7F90-4772-A52B-5864C8C5779AQ38786707-96E461CF-6FC9-4546-BC42-BFD6040EA7CFQ38787244-AB4FB2F8-9F88-4E29-B208-5F67CCF406E5Q38803202-6D7D48FE-F8FC-4ACC-BB77-8115BF76B9D6Q38816712-9A75F246-663F-43D3-BD92-280BAF8EED85Q38941928-70B278CC-D0F5-4379-9029-0C450AB4A5D8Q38961110-5F0F003F-CA21-46DA-8414-F26036897554Q39012229-C16EF4CE-22D0-4AB1-BB50-58692A5EA017Q39172118-C60D06F9-E080-4F8D-9859-3B18F5788C52Q39223563-005BE2B5-E7B1-4957-ABAF-7871A4F568B4Q39306576-6D50D5BC-B05F-413D-9AF0-1DA5BA003821Q39453559-E46EABA0-5FBB-4661-8781-C7124AE6B3CEQ39453583-6516327B-2F86-40CE-B4AC-3A954F69260AQ39455125-D936E49E-69AC-4A73-BF39-D2224EE0182FQ40411498-895E9AC0-A834-461B-9326-AE55F7C8D57EQ41091941-7AE21D33-3107-4E12-89C1-5B4E0DC9AC0AQ41105389-7623C007-3786-4452-B32E-A96A73C65289Q41340207-5C2C50ED-B1E2-449B-B677-F10E45007DFCQ41545171-E523E24F-8977-4C73-B628-E26DFC0A0A2AQ41548672-AC4B2C21-276D-4E24-B5B0-A70365C57E05Q42139529-E771605A-D5F4-4458-8A7D-7F6CEE452A40Q42385734-2E87ED38-988F-4684-9662-7D587DF55D82
P2860
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Dual-targeted therapy with tra ...... re, open-label, phase 2 trial.
@ast
Dual-targeted therapy with tra ...... re, open-label, phase 2 trial.
@en
Dual-targeted therapy with tra ...... re, open-label, phase 2 trial.
@nl
type
label
Dual-targeted therapy with tra ...... re, open-label, phase 2 trial.
@ast
Dual-targeted therapy with tra ...... re, open-label, phase 2 trial.
@en
Dual-targeted therapy with tra ...... re, open-label, phase 2 trial.
@nl
prefLabel
Dual-targeted therapy with tra ...... re, open-label, phase 2 trial.
@ast
Dual-targeted therapy with tra ...... re, open-label, phase 2 trial.
@en
Dual-targeted therapy with tra ...... re, open-label, phase 2 trial.
@nl
P2093
P50
P921
P3181
P1433
P1476
Dual-targeted therapy with tra ...... re, open-label, phase 2 trial.
@en
P2093
Andrea Bertotti
Andrea Cassingena
Calogero Lauricella
Emanuele Valtorta
Erika Martinelli
Fortunato Ciardiello
Giovanna Marrapese
Katia Bencardino
Laura Palmeri
Patrizia Racca
P304
P3181
P356
10.1016/S1470-2045(16)00150-9
P50
P577
2016-06-01T00:00:00Z